Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5526545 | 0.89 | PARP1 (0.59) | PARP1OPRK1OPRM1KCNH2KDM4E | |
| SCHEMBL5529512 | 0.89 | PARP1 (0.65) | PARP1KDM4EHRH3 | |
| SCHEMBL5525259 | 0.87 | PARP1 (0.62) | PARP1KDM4EALDH1A1LMNAHTT | |
| SCHEMBL5524885 | 0.85 | PARP1 (0.60) | PARP1KDM4EALDH1A1LMNAHTT | |
| SCHEMBL5527848 | 0.82 | PARP1 (0.65) | PARP1KDM4EALDH1A1LMNAHTT | |
| SCHEMBL5530505 | 0.82 | PARP1 (0.59) | PARP1KDM4EHRH3 | |
| SCHEMBL4791264 | 0.82 | PARP1 (0.61) | PARP1KDM4EHRH3 | |
| SCHEMBL5520399 | 0.82 | PARP1 (0.61) | PARP1KDM4EHRH3 | |
| SCHEMBL5520388 | 0.82 | PARP1 (0.55) | PARP1KDM4EALDH1A1 | |
| SCHEMBL5525907 | 0.82 | PARP1 (0.70) | PARP1KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | claimed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | claimed |
| EP-2468748-B1 | Pyrazoloquinolones are potent parp inhibitors | ABBVIE INC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-1989204-B1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8546368-B2 | Pyrazoloquinolones are potent PARP inhibitors | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2468748-A1 | Pyrazoloquinolones are potent parp inhibitors | Abbott Laboratories (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249597-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885OPRK1 2401/4885OPRM1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.